Market Overview

UPDATE: Jefferies Lowers PT on Abbott Laboratories as Top US Pharma Pick

Share:
Related ABT
Weed Vs. Opioids: Nontraditional And Traditional Biotech Take On Wall Street, But Who's Winning?
Global Market For Medical Implants To Hit Nearly $27 Billion In 5 Years
Palisades Hudson Asset Management, L.P. Buys iShares Core S&P Small-Cap, iShares S&P ... (GuruFocus)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), but lowered the price target from $46.00 to $44.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Abbott Laboratories closed on Thursday at $36.30.

Latest Ratings for ABT

DateFirmActionFromTo
May 2017Goldman SachsInitiates Coverage OnNeutral
Mar 2017BMO CapitalDowngradesOutperformMarket Perform
Sep 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

View Comments and Join the Discussion!